First Identification of Rare Exonic and Deep Intronic Splice-Altering Variants in Patients With Beta-Sarcoglycanopathy

Introduction

Sarcoglycanopathies consisting of four subtypes of autosomal recessive limb-girdle muscular dystrophies (LGMD2D, LGMD2E, LGMD2F, and LGMD2C) are caused by biallelic loss-of-function variants in four sarcoglycan genes, including the SGCA, SGCB, SGCD, and SGCG genes encoding the α-, β-, δ-, and γ-sarcoglycan proteins, respectively (1). Recently LGMD2D, LGMD2E, LGMD2F, and LGMD2C are reclassified as limb-girdle muscular dystrophy recessive type 3 (LGMDR3), LGMDR4, LGMDR6, and LGMDR5, respectively (2). A tetrameric subcomplex of four sarcoglycans forms part of the dystrophin-glycoprotein complex (DGC) across the sarcolemma of skeletal and cardiac muscle fibers, which maintains muscle membrane stability during cycles of muscle contraction and relaxation (3). Pathogenic variants in genes encoding DGC components disrupt stability and integrity of the whole complex, leading to the so-called DGC-related muscular dystrophies which comprise sarcoglycanopathies, dystrophinopathies, and α-dystroglycanopathies (4).

Sarcoglycanopathies cover a broad clinical spectrum, ranging from a mild phenotype of asymptomatic increase in serum concentration of creatine kinase (CK) to a severe Duchenne-like muscular dystrophy phenotype, which is overlapping with dystrophinopathies and α-dystroglycanopathies (5). Furthermore, both reduced expression of sarcoglycans and dystrophin are observed in sarcoglycanopathies and dystrophinopathies (5, 6); this makes it difficult to accurately predict the primary genetic defect among them based on muscle immunoanalysis. Thus, the confirmatory diagnosis of a sarcoglycanopathy or dystrophinopathy mainly relies on genetic testing. However, the precise genetic diagnosis of a sarcoglycanopathy or dystrophinopathy is sometimes extremely challenging, as non-canonical splicing site variants, deep intronic splice-altering variants (DISVs), and/or complex structural variants do exist in DMD (7, 8) or sarcoglycan (1, 6, 9–13) genes. To our knowledge, only six non-canonical splicing site variants in SGCA (1, 9, 10), SGCB (6), and SGCG (11, 12) and two DISVs in SGCA (1, 13) have been previously reported, of which the identification required mRNA studies and bioinformatic splicing analysis.

In this study, three patients from two unrelated families with a highly suspected sarcoglycanopathy or dystrophinopathy based on their clinical, muscle MRI, and pathological features were enrolled, for whom multiplex ligation-dependent probe amplification (MLPA) and an exomic next-generation sequencing (NGS) panel failed to yield a definite genetic diagnosis. To identify potential non-coding splice-altering variants that might be missed by the panel and MLPA-analysis, muscle-derived mRNA studies of DMD and sarcoglycan genes were performed in them. Finally, two novel DISVs and a rare exonic splice-altering variant, i.e., an aberrant splicing event induced by a predicted nonsense variant, were first identified in SGCB. Furthermore, we also identified a novel non-canonical splicing variant in SGCB. The three patients harboring the pathogenic compound heterozygous variants in SGCB were eventually diagnosed with beta-sarcoglycanopathy.

Materials and Methods

Patients

Three patients who had an elevated serum CK level and/or progressive muscle weakness were enrolled in this study, including patients F1-II1 and F1-II2 from family 1 (F1-II1 and F1-II2 are siblings) and patient F2-II1 from family 2 (Figures 1A,B). Clinical features were ascertained by review of the medical records and a detailed physical examination. Walking ability was recorded as follows: hyperCKemia with or without exercise-induced myalgia, running with difficulties, unable to run, ambulant with support, and non-ambulant. Each muscle group strength was graded by manual muscle testing. Total muscle strength was calculated using a conversion formula of Medical Research Council (14).

FIGURE 1

Figure 1. Pedigrees and muscle T1-weighted images of patients with beta-sarcoglycanopathy. (A) Family 1. (B) Family 2. Each family member was identified with a pedigree number. Affected members colored in black. The black arrow indicated the proband for each family. Schematics of the trefoil with single fruit sign (C) and the concentric fatty infiltration pattern (D). (E–H) A healthy control. (I–L) Patient F1-II1. (M–P) Patient F2-II1. (I) An axial T1-weighted image of pelvis muscles of patient F1-II1 showing moderate fatty infiltration of the pectineus and obturator externus muscles. Axial T1-weighted images of patient F1-II1 showing moderate fatty infiltration of the adductor longus muscle at proximal thigh level (J) and the concentric fatty infiltration pattern around distal femoral diaphysis (K), which consisted of severe fatty infiltration of the vastus medialis and vastus intermedius muscles with sparing of the vastus lateralis muscle (D). (L) No obvious muscle fatty infiltration was observed in the lower leg muscles of patient F1-II1. (M) Mild fatty infiltration of the pectineus and tensor fasciae latae muscles and severe fatty infiltration of the gluteus maximus muscle were observed in patient F2-II1. Axial T1-weighted images of patient F2-II1 showing the concentric fatty infiltration pattern (O) and the trefoil with single fruit sign at proximal thigh level (N), which consisted of three leaflets formed by relative sparing of the adductor longus, sartorius, and gracilis muscles and one single fruit formed by sparing of the semitendinosus muscle (C). (P) Severe fatty infiltration of the gastrocnemius medialis muscle was observed in patient F2-II1. RF, rectus femoris; VL, vastus lateralis; VI, vastus intermedius; VM, vastus medialis; Sa, sartorius; AL, adductor longus; Gr, gracilis; AM, adductor magnus; BFSH, biceps femoris, short head; BFLH, biceps femoris, long head; ST, semitendinosus; SM, semimembranosus.

The electrocardiogram and echocardiography examinations were performed in patients F1-II1 and F2-II1. Cardiac MRI, including late gadolinium enhancement imaging for scar evaluation, was performed in patient F2-II1. MRI examination of the pelvis, thigh, and lower leg muscles was performed in a healthy control and patients F1-II1 and F2-II1 according to a previously described protocol (5). The extent of fatty infiltration of each individual muscle was assessed and scored on axial T1-weighted images using a modified Mercuri’s scale with 0–5 scores (5). Cumulative scores for fatty infiltration of the pelvis, thigh, and lower leg muscles were calculated in patients F1-II1 and F2-II1.

Muscle Biopsy

Muscle biopsies were obtained from tibialis anterior in patient F2-II1 and biceps brachii in patient F1-II1 and a healthy control subject. The biopsy samples were frozen in isopentane, then cooled in liquid nitrogen, and finally stored at −80°C. Routine histological, histochemical, and immunohistochemical staining were performed in them according to standard protocols (15). Primary monoclonal antibodies against the dystrophin and sarcoglycan proteins were used, including dystrophin-N (amino-terminal), dystrophin-R (rod-domain), dystrophin-C (carboxyl-terminal), α-sarcoglycan, β-sarcoglycan, and γ-sarcoglycan (Novocastra Laboratories, Newcastle) (5, 15).

Routine Genomic Detection Approaches

Multiplex ligation-dependent probe amplification-analysis of DMD, SGCA, SGCB, SGCD, and SGCG (8) was performed in the three patients to detect large exonic deletions or duplications. To detect single-nucleotide variants (SNVs) and small insertions/deletions, we performed an exomic NGS panel (15) in them, which covers exons and flanking intronic sequences of genes known to be associated with Mendelian neuromuscular disorders. Sanger sequencing was performed to validate the genomic variants detected by the panel.

Muscle-Derived mRNA Studies and Genomic Sanger Sequencing

Total muscle RNA was extracted from the remaining muscle tissue using an RNA extraction kit (Invitrogen, La Jolla, CA, United States) and subsequently retrotranscribed to cDNA using a HiScript II Q RT SuperMix kit (Vazyme, Nanjing, China) according to the previous protocols (8, 16). Full length cDNA of DMD (NM_004006.2), SGCA (NM_000023.2), SGCB (NM_000232.4), SGCD (NM_000337.5), and SGCG (NM_000231.2) were, respectively, amplified and Sanger sequenced in overlapping cDNA fragments using a set of primers (Supplementary Tables 1, 2). Aberrant cDNA fragments were analyzed by gel electrophoresis, and normal and blank controls were included in each analysis.

TA cloning was performed when the direct reverse transcription-polymerase chain reaction (RT-PCR) analysis of cDNA fragments failed to identify various transcripts. The purified PCR products of the aberrant transcripts were reacted with a T vector assay (pClone007 Cloning Vector Kit, TSV-007, Tsingke, Beijing, China) and then cloned into competent cells. After the reaction on ice, in a water bath with 42°C, and on ice again, the reaction was incubated in Lysogeny Broth medium. The competent cells were spread on the plate and grown overnight at 37°C. Selected colonies were inoculated in Lysogeny Broth/Ampicillin medium and shaken overnight at room temperature. The plasmids were digested with restriction enzymes and then Sanger sequenced using the primers M13R (CAGGAAACAGCTATGACC) and M13F (TGTAAAACGACGGCCAGT) (17). Genomic Sanger sequencing around the sites from which aberrant transcripts were produced was performed to detect possible splice-altering variants. The primers used for the amplification and sequencing of the genomic DNA were described in Supplementary Table 3. Segregation studies, including the detected genomic variants and phenotypes, were performed in both families.

Bioinformatic Analyses

The Human BLAT Search tool was used to search genomic sequences (GRCh37/hg19) that were homologous to the aberrant transcripts. The Human Splicing Finder tool (18) was used to predict alterations in essential splicing signals and splicing regulatory elements caused by the detected genomic variants. The genomic variants, RNA variants, and protein variants identified in this study were described according to the Human Genome Variation Society nomenclature (19). Pathogenicity of each detected genomic variant was interpreted and classified according to the American College of Medical Genetics (ACMG) guidelines (20).

Results

Clinical, Muscle MRI, and Pathological Characteristics

Patient F1-II1 is a 14-year-old adolescent boy who presented progressive lower limb weakness since 5-years of age. He had a positive Gowers’ sign at 7-years of age and waddling gait at 12-years of age. Physical examination confirmed that he had proximal muscle weakness with total muscle strength of 91%, calf hypertrophy, and moderate bilateral tendon contractures. Currently, at 14-years of age, he has difficulties in running and no cardiac involvement in terms of clinical manifestations, electrocardiogram, and echocardiography. His serum CK level was markedly elevated in every test (range 7,259–10,085 IU/L; normal 25–170 IU/L). His muscle MRI examination showed moderate muscle fatty infiltration of the pelvis and thigh muscles compared to a healthy control (Figures 1E–J), and no obvious muscle fatty infiltration of the lower leg muscles (Figure 1L). Moreover, his muscle MRI examination showed a distinctive muscle involvement pattern, the concentric fatty infiltration pattern around distal femoral diaphysis (Figures 1D,K), which is highly specific for a sarcoglycanopathy (5). The cumulative score for fatty infiltration of the lower extremity muscles was 37. His muscle biopsy and immunohistochemical staining revealed a muscular dystrophic pattern, a mild reduction of α-sarcoglycan, complete deficiency of β-sarcoglycan, a partial reduction of γ-sarcoglycan, a very slight reduction of dystrophin-N, and positive expression of dystrophin-C and dystrophin-R compared to a normal control (Figures 2A–N).

FIGURE 2

Figure 2. Pathologic features of patients with beta-sarcoglycanopathy. (H,O) Hematoxylin-eosin staining showing a muscular dystrophic pattern in patients F1-II1 and F2-II1. (A–G) A normal control showing positive expression of sarcoglycans and dystrophin. (H–N) Patient F1-II1 showing a mild reduction of α-sarcoglycan, complete deficiency of β-sarcoglycan, a partial reduction of γ-sarcoglycan, a very slight reduction of dystrophin-N, and positive expression of dystrophin-C and dystrophin-R. (O–U) Patient F2-II1 showing a severe reduction of α-sarcoglycan, absent expression of β-sarcoglycan, a partial reduction of γ-sarcoglycan, a very slight reduction of dystrophin-N, positive expression of dystrophin-C, and a partial reduction of dystrophin-R. 200× magnification.

Patient F1-II2 is a 4-year-old girl who presented to our hospital because of her brother’s admission. She has an elevated level of serum CK (4,210 IU/L). She has no muscle weakness, calf hypertrophy, or tendon contractures confirmed by the physical examination. She did not undergo a muscle MRI examination or muscle biopsy, as it was performed in her brother, patient F1-II1.

Patient F2-II1 is a 17-year-old adolescent boy. He presented to our hospital at 17-years of age because of exercise-induced myalgia and myalgia since 9-years of age. He was confirmed to have a sensorineural hearing loss at 10-years of age. He had a positive Gowers’ sign at 11-years of age and waddling gait at 14-years of age. He had suffered from chest distress and exercise intolerance since 14-year-old. Physical examination confirmed that he had both proximal and distal muscle weakness with total muscle strength of 77%, calf hypertrophy, and severe bilateral tendon contractures. He is now unable to run or complete the Gowers’ maneuver and confirmed to have a dilated cardiomyopathy. His electrocardiogram showed a right bundle branch block. His echocardiography revealed left ventricular dilatation, diffuse hypokinesis of left ventricular wall motion, and reduced cardiac output with a left ventricular ejection fraction of 41%. His cardiac muscle MRI confirmed wall motion abnormalities, left ventricular enlargement, and partial fibrosis with an epicardial and mesocardial scar along the inferior and lateral walls of the left ventricle. His serum CK level was elevated in every test, ranging from 1,750 to 10,000 IU/L. His muscle MRI examination revealed mild fatty infiltration of the pectineus and tensor fasciae latae muscles and severe fatty infiltration of the gluteus maximus muscle (Figure 1M). Furthermore, his muscle MRI examination showed not only the concentric fatty infiltration pattern (Figure 1O) but also the trefoil with single fruit sign at proximal thigh level that is highly specific for a dystrophinopathy (Figures 1C,N). Severe fatty infiltration of the gastrocnemius medialis muscle was observed in patient F2-II1 (Figure 1P). The cumulative score for fatty infiltration was 58. His muscle biopsy and immunohistochemical staining showed a muscular dystrophic pattern, a severe reduction of α-sarcoglycan, absent expression of β-sarcoglycan, a partial reduction of γ-sarcoglycan, a very slight reduction of dystrophin-N, positive expression of dystrophin-C, and a partial reduction of dystrophin-R (Figures 2O–U).

Based on the clinical phenotypes, family history, and muscle MRI and pathological features, the three patients enrolled in this study were highly suspected of having a sarcoglycanopathy or dystrophinopathy.

Pathogenic Variants Identified in This Study

Variants Detected in Routine Genomic Detection Approaches

Multiplex ligation-dependent probe amplification-analysis of DMD, SGCA, SGCB, SGCD, and SGCG didn’t detect any large exonic deletions or duplications in the three patients. The NGS panel detected a variant of uncertain significance in the non-canonical splicing site region of SGCB, the c.243 + 6T > A variant in patients F1-II1 and F1-II2 (Table 1). In patient F2-II1, the NGS panel detected a heterozygous nonsense variant in SGCB, the c.334C > T, p.(Gln112*) variant, and a homozygous frameshift variant in GJB2, NM_004004.5:c.235del, p.(Leu79Cysfs*3). The GJB2 variant has been previously reported as a pathogenic variant responsible for autosomal recessive non-syndromic hearing impairment (21). In addition, c.334C > T has also been reported as a pathogenic SGCB variant (15).

TABLE 1

Table 1. Pathogenic SGCB variants identified in our patients with beta-sarcoglycanopathy.

Variants Identified via mRNA Studies and Genomic Sanger Sequencing

The RT-PCR analysis of DMD, SGCA, SGCD, and SGCG mRNA didn’t reveal any aberrant transcripts in patients F1-II1 and F2-II1. Alterations in splice site strength caused by splice-altering variants in SGCB were summarized in Supplementary Table 4. RT-PCR amplification of the SGCB exons 1–5 from patient F1-II1 showed that the upper band was larger than the expected band, while the lower band was almost the same size as the expected band (Figure 3A). Direct Sanger sequencing of the aberrant SGCB transcripts could not recognize the overlapping sequences (Figure 3B). Thus, TA cloning of the aberrant cDNA fragments was performed, which revealed two aberrant SGCB splicing events, i.e., a 10-base pair (bp) sequence insertion (Figure 3C) and an 87-bp insertion of intron 2 sequence (pseudoexon 1, PE1) between SGCB exons 2 and 3 (Figure 3D), and the normal splicing of SGCB exons 2–3 (Figure 3E). Sanger sequencing of the genomic SGCB sequence around exon 2 and the PE1 revealed the c.243 + 6T > A variant (Figure 3F) and a deep intronic SNV, c.243 + 1558C > T, adjacent to the PE1 (Figure 3G). The non-canonical splicing site variant, c.243 + 6T > A, disrupted the natural donor splice site (5′ ss) of exon 2 and activated a cryptic 5′ ss in intron 2, resulting in the partial intron inclusion of a 10-bp sequence into the mature SGCB transcript (Figure 3H and Supplementary Table 4). The c.243 + 1558C > T variant created a new 5′ ss in intron 2 that was paired with the adjacent cryptic acceptor splice site (3′ ss), causing the activation of PE1 (Figure 3I and Supplementary Table 4). Both the partial intron inclusion and PE1 activation transcripts encoded a frameshift and premature termination codon (Table 1) that were targeted for degradation by nonsense-mediated decay (NMD), leading to the complete deficiency of β-sarcoglycan observed in patient F1-II1 (Figure 2J).

FIGURE 3

Figure 3. Muscle-derived mRNA studies and genomic SGCB sequencing of patient F1-II1. (A) RT-PCR amplification of the aberrant SGCB transcripts from patient F1-II1 showed that the upper band was larger than the expected band, while the lower band was almost the same size as the expected band. (B) Direct Sanger sequencing of the aberrant SGCB transcripts could not recognize the overlapping sequences. (C–E) TA cloning of the aberrant cDNA fragments revealed a 10-bp sequence insertion and an 87-bp insertion of intron 2 sequence between SGCB exons 2 and 3 (PE1), and the normal splicing of SGCB exons 2–3. (F) Sanger sequencing of the genomic sequence around SGCB exon 2 revealed the c.243 + 6T > A variant. (G) Sanger sequencing of the genomic SGCB sequence around the PE1 revealed the c.243 + 1558C > T variant. (H) The schematic of the aberrant insertion of 10-bp sequence between SGCB exons 2 and 3 caused by the c.243 + 6T > A variant in SGCB. (I) The schematic of the aberrant 87-bp insertion of intron 2 sequence between SGCB exons 2 and 3 caused by the c.243 + 1558C > T variant in SGCB. Ctr1, a normal control; Blank, a reagent control; PE, pseudoexon; RT-PCR, reverse transcription-polymerase chain reaction; F, fragment; bp, base pair; PTC, premature termination codon; NMD, nonsense-mediated decay.

Reverse transcription-polymerase chain reaction amplification of the SGCB exons 1–5 from patient F2-II1 showed three bands with varying size (Figure 4A). Direct Sanger sequencing of the aberrant SGCB transcripts could not recognize the overlapping sequences (Figure 4B). TA cloning of the aberrant cDNA fragments was therefore performed and revealed two aberrant SGCB splicing events, i.e., a 106-bp insertion of intron 2 sequence between SGCB exons 2 and 3 (PE2; Figure 4C) and a 97-bp truncation of SGCB exon 3 (Figure 4D), and the normal splicing of SGCB exons 3–4 (Figure 4E). Sanger sequencing of the genomic SGCB sequence around the PE2 and exon 3 revealed a deep intronic SNV, c.243 + 1576C > G, adjacent to the PE2 (Figure 4F), and the c.334C > T variant (Figure 4G). The c.243 + 1576C > G variant created a new 5′ ss in intron 2 that was paired with the adjacent cryptic 3′ ss, resulting in the activation of PE2 (Figure 4H and Supplementary Table 4). Unexpectedly, the predicted nonsense variant, c.334C > T, p.(Gln112*) in SGCB, created a new 5′ ss in exon 3 that was stronger than the natural 5′ ss of exon 3, eventually causing a 97-bp deletion of SGCB exon 3 (Figure 4I and Supplementary Table 4). Hence, the predicted nonsense variant is actually an exonic splice-altering variant. Both the PE2 activation and exon truncation transcripts encoded a frameshift and premature termination codon (Table 1), which were targeted for degradation by NMD and resulted in the absent expression of β-sarcoglycan observed in patient F2-II1 (Figure 2Q).

FIGURE 4

Figure 4. Muscle-derived mRNA studies and genomic SGCB sequencing of patient F2-II1. (A) RT-PCR amplification of the aberrant SGCB transcripts from patient F2-II1 showed three bands with varying size. (B) Direct Sanger sequencing of the aberrant SGCB transcripts could not recognize the overlapping sequences. (C–E) TA cloning of the aberrant cDNA fragments revealed a 106-bp insertion of intron 2 sequence between SGCB exons 2 and 3 (PE2), a 97-bp truncation of SGCB exon 3, and the normal splicing of SGCB exons 3–4. (D) The Sanger chromatogram showed the beginning sequences of SGCB exon 3 and indicated the 97-bp truncation of SGCB exon 3 (NM_000232.4:r.333_429del). (F) Sanger sequencing of the genomic SGCB sequence around the PE2 revealed the c.243 + 1576C > G variant. (G) Sanger sequencing of the genomic SGCB exon 3 sequence revealed the c.334C > T variant. (H) The schematic of the aberrant 106-bp insertion of intron 2 sequence between SGCB exons 2 and 3 caused by the c.243 + 1576C > G variant in SGCB. (I) The schematic of the aberrant 97-bp truncation of SGCB exon 3 caused by the c.334C > T variant in SGCB. Ctr1, a normal control; Blank, a reagent control; PE, pseudoexon; RT-PCR, reverse transcription-polymerase chain reaction; F, fragment; bp, base pair; PTC, premature termination codon; NMD, nonsense-mediated decay.

The two DISVs (c.243 + 1558C > T and c.243 + 1576C > G) and one non-canonical splicing site variant (c.243 + 6T > A) in SGCB identified in this study are novel variants, as they are not reported in the literature and absent from population and disease-specific databases (20), including the Genome Aggregation Database, ClinVar, and Leiden Open Variation Database. Segregation studies confirmed that c.243 + 1558C > T and c.243 + 6T > A are compound heterozygous variants in patients F1-II1 and F1-II2, and c.243 + 1576C > G and c.334C > T in patient F2-II1. All four SGCB variants identified in our patients are classified as a pathogenic variant according to the ACMG guidelines (20), as each of them fulfills the criteria described in Table 1. The three patients harboring the pathogenic compound heterozygous variants in SGCB were eventually diagnosed with beta-sarcoglycanopathy.

Discussion

In this study, three patients from two unrelated families were highly suspected of a sarcoglycanopathy or dystrophinopathy based on their clinical, muscle MRI, and pathological features, which drove us to perform muscle-derived mRNA studies of DMD and sarcoglycan genes after indefinite findings in routine genetic testing in them. Finally, we identified rare intronic and exonic splice-altering variants in SGCB and confirmed the genetic diagnosis of them. These cases are an example of how clinical, radiological, and pathological data can facilitate the further genetic testing in rare Mendelian diseases.

The confirmatory diagnosis of a sarcoglycanopathy or dystrophinopathy relies primarily on genetic testing, as they share overlapping characteristics in clinical, radiological, and pathological features (5). To date, there is no proven curable treatment for sarcoglycanopathy or dystrophinopathy. Therefore, prenatal diagnosis that requires precise detection of pathogenic variants in DMD or sarcoglycan genes can be of great value for families with a sarcoglycanopathy or dystrophinopathy. Like the other monogenic diseases, most of the pathogenic variants in DMD or sarcoglycan genes are in coding regions or canonical splice sites (4, 8, 12, 15, 22), which can be detected by routine genomic detection approaches. However, pathogenic non-coding variants including non-canonical splicing site variants and DISVs do exist in DMD (7, 8) or sarcoglycan (1, 6, 9–13) genes, which are simply missed by the routine genomic detection approaches. The identification of non-coding splicing variants requires mRNA studies and bioinformatic splicing analysis in addition to the genomic sequencing (8, 23). Therefore, after indefinite findings in routine approaches in three patients with a suspected sarcoglycanopathy or dystrophinopathy, we performed muscle-derived mRNA studies of DMD and sarcoglycan genes and relevant bioinformatic splicing analysis in them, including direct RT-PCR analysis and TA cloning. As the direct RT-PCR analysis of SGCB mRNA failed to identify the various transcripts observed, TA cloning was used in this study. Finally, we successfully identified three novel intronic and one exonic splice-altering variants in SGCB via the combination of mRNA studies and genomic Sanger sequencing, which confirmed the genetic diagnosis of them. The novel intronic SGCB variants identified in our patients emphasizes the potential role of underdetected DISVs in rare Mendelian diseases.

To our knowledge, only six non-canonical splicing site variants, including four in SGCA (1, 9, 10), one in SGCB (6), and two in SGCG (11, 12), and two DISVs in SGCA (1, 13) have been previously reported. Similar to the previously reported non-canonical splicing site variant in intron 2 of SGCB (c.243 + 5G > A) (6), the c.243 + 6T > A identified in our study is also located in intron 2. Different to the two reported DISVs in SGCA, i.e., the c.585-31_585-24del and c.37 + 23G > A variants that are not too far from the exon-intron junctions (1, 13), the two novel DISVs in SGCB (c.243 + 1558C > T and c.243 + 1576C > G) identified in our study are quite far from the exon-intron junctions, which is the first identification of DISVs in SGCB. All the reported and newly discovered non-canonical splicing site variants and DISVs in SGCB are located in intron 2, suggesting that intron 2 is a hotspot region for intronic variants in β-sarcoglycanopathy. Genetic investigation of the region (chr4:52898000-52899000; GRCh37/hg19) should be performed in genetically undiagnosed patients with a highly suspected sarcoglycanopathy. Unexpectedly, we found that a reported nonsense variant in SGCB, the c.334C > T variant, is actually an exonic splice-altering variant, as it created a new donor splice site in exon 3 that was stronger than the natural one and resulted in the exon truncation followed by NMD, which is also the first identification of exonic splice-altering variant in SGCB. All the aberrant SGCB transcripts identified in our patients encoded a frameshift and premature termination codon followed by NMD and resulted in the complete deficiency of β-sarcoglycan. This indicates that in addition to coding variants that can directly change a protein sequence, aberrant pre-mRNA splicing that induced by intronic or exonic splice-altering variants can also be devastating for the encoded protein.

The clinical characteristics of our patients with β-sarcoglycanopathy are similar to the findings of previous studies (1, 10, 15, 24, 25). We find that patients with β-sarcoglycanopathy may also have another Mendelian disease, like the sensorineural hearing loss phenotype caused by pathogenic GJB2 variants observed in patient F2-II1. Presence of the two distinct Mendelian forms, i.e., β-sarcoglycanopathy and GJB2-related hearing impairment, in a same patient highlights the significance of genetic counseling in patients with β-sarcoglycanopathy. Clinical geneticists, pediatricians, and neurologists should be aware of this possibility. Our previous studies have confirmed that the concentric fatty infiltration pattern around distal femoral diaphysis, a selective fatty infiltration pattern observed on muscle MRI, is highly specific for sarcoglycanopathies with pathogenic coding variants in sarcoglycan genes (5). This study first confirms that β-sarcoglycanopathy with pathogenic non-coding variants can also present the concentric fatty infiltration pattern. In addition, patient F2-II1 with β-sarcoglycanopathy showed both the concentric fatty infiltration pattern and the trefoil with single fruit sign that is highly specific for a dystrophinopathy. These overlapping muscle MRI patterns indicate that different defects in the components of DGC can cause impairment of the sarcolemma integrity and stability (3), which might lead to some similarities among the affected skeletal muscles (5).

In conclusion, we successfully identified three novel intronic and one exonic splice-altering variants in SGCB via the combination of muscle-derived mRNA studies and genomic Sanger sequencing, which is the first identification of rare exonic and DISVs in SGCB. Our study expands the clinical and genetic spectrum of β-sarcoglycanopathy and indicates that intronic and exonic splice-altering variants are also important causes of sarcoglycanopathies.

Data Availability Statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Ethics Statement

The studies involving human participants were reviewed and approved by the Ethics Committee at Peking University First Hospital. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

Author Contributions

ZX, CS, WZ, and YY conceived and planned the study, take full responsibility for the manuscript, and contributed to the revisions of the manuscript. ZX, CS, and WZ contributed to the methodology of the study. ZX, CS, MY, YZ, LM, FL, and YL conducted the clinical and radiological study. ZX, CS, CL, XC, QG, and JD conducted the genetic research. DX and LW performed the experiments of muscle-derived RNA studies. ZX and ZW checked all the genetic analyses. ZX and CS took the lead in writing the manuscript. WZ and YY supervised the study. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by a grant from the Beijing Municipal Science and Technology Commission (grant number: Z191100006619034).

Conflict of Interest

DX and LW were employed by Running Gene Inc., Beijing, China. They performed the experiments of muscle-derived RNA studies.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2022.900280/full#supplementary-material

References

1. Alonso-Pérez J, González-Quereda L, Bello L, Guglieri M, Straub V, Gallano P, et al. New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy. Brain. (2020) 143:2696–708. doi: 10.1093/brain/awaa228

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Straub V, Murphy A, Udd B, LGMD Workshop Study Group. 229th ENMC international workshop: limb girdle muscular dystrophies – Nomenclature and reformed classification Naarden, the Netherlands, 17–19 March 2017. Neuromuscul Disord. (2018) 28:702–10. doi: 10.1016/j.nmd.2018.05.007

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Gao QQ, McNally EM. The dystrophin complex: structure, function, and implications for therapy. Compr Physiol. (2015) 5:1223–39. doi: 10.1002/cphy.c140048

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Nallamilli BRR, Chakravorty S, Kesari A, Tanner A, Ankala A, Schneider T, et al. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin Transl Neurol. (2018) 5:1574–87. doi: 10.1002/acn3.649

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Xie Z, Xie Z, Yu M, Zheng Y, Sun C, Liu Y, et al. Value of muscle magnetic resonance imaging in the differential diagnosis of muscular dystrophies related to the dystrophin-glycoprotein complex. Orphanet J Rare Dis. (2019) 14:250. doi: 10.1186/s13023-019-1242-y

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Klinge L, Dekomien G, Aboumousa A, Charlton R, Epplen JT, Barresi R, et al. Sarcoglycanopathies: can muscle immunoanalysis predict the genotype? Neuromuscul Disord. (2008) 18:934–41. doi: 10.1016/j.nmd.2008.08.003

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Waddell LB, Bryen SJ, Cummings BB, Bournazos A, Evesson FJ, Joshi H, et al. WGS and RNA studies diagnose noncoding DMD variants in males with high creatine kinase. Neurol Genet. (2021) 7:e554. doi: 10.1212/nxg.0000000000000554

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Xie Z, Sun C, Liu Y, Yu M, Zheng Y, Meng L, et al. Practical approach to the genetic diagnosis of unsolved dystrophinopathies: a stepwise strategy in the genomic era. J Med Genet. (2021) 58:743–51. doi: 10.1136/jmedgenet-2020-107113

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Trabelsi M, Kavian N, Daoud F, Commere V, Deburgrave N, Beugnet C, et al. Revised spectrum of mutations in sarcoglycanopathies. Eur J Hum Genet. (2008) 16:793–803. doi: 10.1038/ejhg.2008.9

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Guimarães-Costa R, Fernández-Eulate G, Wahbi K, Leturcq F, Malfatti E, Behin A, et al. Clinical correlations and long-term follow-up in 100 patients with sarcoglycanopathies. Eur J Neurol. (2021) 28:660–9. doi: 10.1111/ene.14592

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Lo HP, Cooper ST, Evesson FJ, Seto JT, Chiotis M, Tay V, et al. Limb-girdle muscular dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscul Disord. (2008) 18:34–44. doi: 10.1016/j.nmd.2007.08.009

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Reddy HM, Cho KA, Lek M, Estrella E, Valkanas E, Jones MD, et al. The sensitivity of exome sequencing in identifying pathogenic mutations for LGMD in the United States. J Hum Genet. (2017) 62:243–52. doi: 10.1038/jhg.2016.116

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Gonzalez-Quereda L, Gallardo E, Töpf A, Alonso-Jimenez A, Straub V, Rodriguez MJ, et al. A new mutation of the SCGA gene is the cause of a late onset mild phenotype limb girdle muscular dystrophy type 2D with axial involvement. Neuromuscul Disord. (2018) 28:633–8. doi: 10.1016/j.nmd.2018.06.002

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Scott OM, Hyde SA, Goddard C, Dubowitz V. Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve. (1982) 5:291–301. doi: 10.1002/mus.880050405

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Xie Z, Hou Y, Yu M, Liu Y, Fan Y, Zhang W, et al. Clinical and genetic spectrum of sarcoglycanopathies in a large cohort of Chinese patients. Orphanet J Rare Dis. (2019) 14:43. doi: 10.1186/s13023-019-1021-9

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Jin M, Li JJ, Xu GR, Wang N, Wang ZQ. Cryptic exon activation causes dystrophinopathy in two Chinese families. Eur J Hum Genet. (2020) 28:947–55. doi: 10.1038/s41431-020-0578-z

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Li F, Liu Y, Liu H, Yang J, Zhang F, Feng H. Phenotype and genotype analyses in seven families with dentinogenesis imperfecta or dentin dysplasia. Oral Dis. (2017) 23:360–6. doi: 10.1111/odi.12621

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Desmet FO, Hamroun D, Lalande M, Collod-Béroud G, Claustres M, Béroud C. Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. (2009) 37:e67. doi: 10.1093/nar/gkp215

PubMed Abstract | CrossRef Full Text | Google Scholar

19. den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. (2016) 37:564–9. doi: 10.1002/humu.22981

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. (2015) 17:405–24. doi: 10.1038/gim.2015.30

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Dai P, Yu F, Han B, Liu X, Wang G, Li Q, et al. GJB2 mutation spectrum in 2,063 Chinese patients with nonsyndromic hearing impairment. J Transl Med. (2009) 7:26. doi: 10.1186/1479-5876-7-26

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Alonso-Pérez J, González-Quereda L, Bruno C, Panicucci C, Alavi A, Nafissi S, et al. Clinical and genetic spectrum of a large cohort of patients with δ-sarcoglycan muscular dystrophy. Brain. (2021) 145:596–606. doi: 10.1093/brain/awab301

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Lee H, Huang AY, Wang LK, Yoon AJ, Renteria G, Eskin A, et al. Diagnostic utility of transcriptome sequencing for rare Mendelian diseases. Genet Med. (2020) 22:490–9. doi: 10.1038/s41436-019-0672-1

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Pashun RA, Azari BM, Achar A, Gruber D, Epstein LM, Geraci AP, et al. Intramyocardial fat in family with limb-girdle muscular dystrophy type 2E cardiomyopathy and sudden cardiac death. Circ Cardiovasc Imaging. (2020) 13:e010104. doi: 10.1161/circimaging.119.010104

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Tasca G, Monforte M, Díaz-Manera J, Brisca G, Semplicini C, D’Amico A, et al. MRI in sarcoglycanopathies: a large international cohort study. J Neurol Neurosurg Psychiatry. (2018) 89:72–7. doi: 10.1136/jnnp-2017-316736

PubMed Abstract | CrossRef Full Text | Google Scholar